• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Orexo gets European patent covering OX640 intranasal dry powder adrenaline

The European Patent Office (EPO) has granted Orexo a patent (EP 3962455B1) covering the company's OX640 intranasal dry powder adrenaline, which is in Phase 1 development for the emergency treatment of anaphylaxis. According to the company, the European patent will protect OX640 until May 2041. OX640 intranasal adrenaline is based on the same technology as the … [Read more...] about Orexo gets European patent covering OX640 intranasal dry powder adrenaline

Hikma launches Ryaltris nasal spray in the US

Hikma Pharmaceuticals has launched Ryaltris olopatadine / mometasone nasal spray in the US, the company said. Hikma acquired US rights to Ryaltris in February 2020, and the FDA approved Glenmark's NDA for the nasal spray for the treatment of seasonal allergic rhinitis in January 2022. The company's US catalog includes several other nasal sprays, including … [Read more...] about Hikma launches Ryaltris nasal spray in the US

Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing

A US District Court has ordered Wockhardt subsidiary Morton Grove Pharmaceuticals "to stop manufacturing and distributing drugs alleged to be adulterated." The Morton Grove facility manufactured fluticasone propionate nasal sprays in addition to other products. The company has signed a consent decree agreeing to cease production, to destroy already manufactured drugs, … [Read more...] about Wockhardt subsidiary Morton Grove Pharmaceuticals ordered to stop manufacturing

Nob Hill names Noel Greenberger as CEO, gets $1.7 million grant for development of a nebulized dry powder antifungal

Dry powder nebulizer developer Nob Hill Therapeutics announced the appointment of Noel Greenberger as its new CEO, replacing interim CEO Yun Li as of September 1, and said that it has received a Department of Health and Human Services (HHS) Small Business Innovation Research (SBIR) Phase 2 grant of up to $1.73 million for development of a dry powder antifungal … [Read more...] about Nob Hill names Noel Greenberger as CEO, gets $1.7 million grant for development of a nebulized dry powder antifungal

SaNOtize raises $24 million for development of NONS nitric oxide nasal spray

SaNOtize announced that it has closed a $24 million Series B funding round led by Horizons Ventures and OurCrowd with proceeds to go towards continued development of the company’s NONS nitric oxide nasal spray. The company initiated a Phase 3 trial of NONS for the treatment of COVID-19 in June 2021 and announced positive results from that study in July 2022. In August … [Read more...] about SaNOtize raises $24 million for development of NONS nitric oxide nasal spray

Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant

Windtree Therapeutics said that it has signed a deal with Lee’s Pharmaceutical and its subsidiary Zhaoke Pharmaceutical giving Lee's global rights to develop and commercialize Windtree surfactants for any potential indications, including Aerosurf aerosolized KL4 surfactant for the treatment of premature infants with respiratory distress syndrome. According to … [Read more...] about Lee’s acquires global rights to Windtree’s Aerosurf aerosolized KL4 surfactant

NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis

The US National Institutes of Health (NIH) has published a notice in the Federal Register regarding the availability of intellectual property related to the use of inhaled thrombin inhibitors for the treatment of lung fibrosis caused by SARS-CoV-2 infection. The notice says that the technology "is available for licensing to achieve expeditious commercialization of … [Read more...] about NIH announces availability of licensing for IP related to nebulized thrombin inhibitors for the treatment of SARS-CoV-2-induced lung fibrosis

HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray

HDT Bio announced that it has received a grant of ~$1.8 million from the US Army Medical Research Acquisition Activity for development of the company's HDT-201 RNA-based nasal spray for the prevention and treatment of viral infections. The company said that the funding will support pre-clinical safety and potency studies, with clinical trials anticipated to begin in … [Read more...] about HDT Bio Gets $1.8 million for US Army for development of antiviral nasal spray

Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans

Canadian biotech Ceapro announced the expansion of an existing collaboration with McMaster University for development of inhaled yeast beta glucans for the prevention and treatment of lung fibrosis caused by COVID-19. According to Ceapro, the team has already successfully created inhalable yeast beta glucan particles via PGX and now plans to optimize delivery and … [Read more...] about Ceapro expands collaboration with McMaster University on development of inhaled yeast beta glucans

Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation

Harm Reduction Therapeutics announced that it has signed a commercial supply agreement for its RiVive (HRT001) intranasal naloxone after the FDA granted Fast Track designation to the nasal spray, which is in development as a low cost OTC product for the reversal of opioid overdose. HRT did not name the company it contracted with but said that RiVive would be … [Read more...] about Harm Reduction signs supply agreement for RiVive naloxone nasal spray after getting Fast Track designation

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews